Pharmacy Technician Pulse

Clinical trial begins of lung cancer immunotherapeutic

pharmaphorum

JANUARY 18, 2022

Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has begun a phase I/IIa clinical trial of a new lung cancer vaccine. Nigel Blackburn, director of cancer research UK’s Centre for Drug Development, said in a statement.

Immunization

Immunization Vaccines Hospitals

AstraZeneca’s Imfinzi tackles another type of lung cancer with latest trial win

Fierce Pharma

APRIL 5, 2024

AstraZeneca's Imfinzi has delivered positive clinical data in another type of lung cancer, building on the immunotherapy’s existing FDA clearance in stage 3 non-small cell lung cancer and extensive | AstraZeneca's Imfinzi has delivered positive clinical data in another type of lung cancer, building on the immunotherapy’s existing FDA clearance (..)

FDA

AST-001 by Ascentawits Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer.

Domvanalimab Combination Shows Clinically Meaningful Progression-Free Survival in Lung Cancer

Pharmacy Times

DECEMBER 1, 2022

Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

Pharmafile

APRIL 5, 2024

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) (..)

EGFR inhibitor could provide major advance in lung cancer

European Pharmaceutical Review

FEBRUARY 21, 2024

Small molecule treatment TAGRISSO ® (osimertinib) demonstrated a “statistically significant and highly clinically meaningful improvement” in progression-free survival (PFS) for Stage III lung cancer patients, AstraZeneca has confirmed. This was established from positive high-level results seen in the LAURA Phase III trial.

Chemotherapy

Trastuzumab Deruxtecan Shows Clinical Benefit as Second-Line Therapy for Lung Cancer

Pharmacy Times

SEPTEMBER 20, 2023

In many countries, trastuzumab deruxtecan is the only HER2-targeted therapy approved for patients with this HER2–mutant metastatic non-small cell lung cancer.

Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer

Fierce Pharma

SEPTEMBER 22, 2023

Following a series of trial shortfalls this year in melanoma, colorectal cancer and head and neck squamous cell carcinoma, the duo has missed the mark in yet another set of clinical trials—this time in non-small cell lung cancer. . | Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break.

AFNT-211 by Affini-T Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

AFNT-211 is under clinical development by Affini-T Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

STAT

FEBRUARY 29, 2024

BlossomHill is preparing to start human clinical studies of potential medicines that could someday treat blood cancer and lung cancer. Among her targets: a competitor to AstraZeneca’s Tagrisso, one of the best-selling cancer pills on the market.

Prothea debuts with $13m to develop cancer diagnostics and treatment

Pharmaceutical Technology

APRIL 9, 2024

Prothea plans to use the funds to start clinical trial for cancer imaging, biopsy and laser ablation treatment in lung cancer patients.

GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer.

New Amgen immunotherapy could treat common solid tumour

European Pharmaceutical Review

NOVEMBER 24, 2023

Amgen’s new immunotherapeutic agent Tarlatamab has been shown in a Phase II trial to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer patients. The international DeLLphi-301study was investigated as a new anti-cancer treatment option for patients previously considered to be beyond treatment.

Dosage

Dosage Hospitals

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

DF-4101 is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer.

Research predicts 2029 small molecule oncology market leaders

European Pharmaceutical Review

OCTOBER 12, 2023

Strong demand for small molecules as treatment for non-small cell lung cancer (NSCLC) in the eight major markets means that the small molecule treatment market for the disease is expected to reach over $15 billion by 2029. As the current landscape for lung cancer therapeutics stands, 39 small molecules have been commercialised.

FDA

Clinical Research Demonstrates Positive Impact of Genomic Testing for Patients with Non-small Cell Lung Cancer

Pharmacy Times

OCTOBER 2, 2023

Researchers utilize data from Florida Cancer Specialists & Research Institute to inform results.

Trastuzumab Deruxtecan Shows Clinically Meaningful Response in Non-Small Cell Lung Cancer

Pharmacy Times

SEPTEMBER 13, 2022

mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer. Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% in the 5.4 mg/kg arm and 6.4

Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung Cancer

Pharmacy Times

JUNE 5, 2023

In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.

STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain

STAT

JUNE 6, 2023

CHICAGO — A medical device made by Novocure that creates electric fields in the lungs via wearable skin patches extended the survival of patients with lung cancer in a clinical trial, researchers reported Tuesday. Delivering additional sales, however, could be a significant challenge.

Chemotherapy

Chemotherapy Immunization

Sanofi stops development of lung cancer drug

European Pharmaceutical Review

DECEMBER 22, 2023

French pharmaceutical giant Sanofi announced that it is ending the development programme evaluating tusamitamab ravtansine as a monotherapy for certain patients with metastatic non-squamous, non-small cell lung cancer (NSCLC). It may be overexpressed in many different cancer types.

Labelling

Lung Cancer Patients Show Better Overall Survival With Atezolizumab in Clinical Trial

Pharmacy Times

AUGUST 30, 2022

Atezolizumab meets its primary endpoint of overall survival for patients with resected non-small cell lung cancer across most subgroups.

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

SEPTEMBER 29, 2023

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Immunization

Future lung cancer risk predicted from single low-dose CT scan

Hospital Pharmacy Europe

FEBRUARY 1, 2023

The use of low-dose CT screening has been shown to reduce mortality from lung cancer. The use of low-dose CT screening has been shown to reduce mortality from lung cancer. Nevertheless, the efficiency of lung cancer screening could be improved by individualising the assessment of future cancer risk.

Hospitals

Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

Pharmafile

SEPTEMBER 1, 2023

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of early-stage anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), met its primary endpoint of disease-free survival (DFS).

Chemotherapy

AstraZeneca backs AI-based lung cancer diagnosis pilot in UK

pharmaphorum

JANUARY 17, 2023

and a clinical group in the UK to test an artificial intelligence-powered technology to help radiologists detecting lung cancer in chest X-rays. Greater Manchester has been selected as the site for the trial, as rates of lung cancer there are among the highest in the UK, said the partners. ” AZ and Qure.ai

Osimertinib Significantly Improves Disease-Free Survival in EGFR-Mutated Lung Cancer

Pharmacy Times

SEPTEMBER 14, 2022

Researchers at the European Society for Medical Oncology Congress presented findings that show osimertinib may clinically reduce the risk of lung cancer recurrence.

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

Novel vaccine delivers significant survival in lung cancer trial

European Pharmaceutical Review

SEPTEMBER 12, 2023

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. The findings also demonstrated a clinically meaningful benefit in median overall survival of 3.6 percent versus 27.5

Vaccines

Vaccines Chemotherapy Immunization

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Small Cell Lung Cancer.

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer.

NICE recommends new treatment for EGFR-positive lung cancer

European Pharmaceutical Review

NOVEMBER 17, 2022

Final draft guidance published by the National Institute for Health and Care Excellence (NICE), recommends Mobocertinib (Exkivity), a new therapy that helps slow cancer growth in adults with epidermal growth factor receptor ( EGFR ) exon 20+ non-small-cell lung cancer (NSCLC), who have already received platinum-based chemotherapy.

Chemotherapy

STAT+: FDA finds ‘potential systemic bias’ in Amgen’s KRAS drug trial ahead of advisory meeting

STAT

OCTOBER 3, 2023

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

FDA

Roche subcutaneous cancer immunotherapy granted MHRA approval

European Pharmaceutical Review

AUGUST 29, 2023

The Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised the first subcutaneous formulation of an anti-PD-(L)1 cancer immunotherapy to be made available to patients in Great Britain. Tecentriq SC will be available on the NHS in Great Britain for certain types of lung, bladder, breast, and liver cancer.

Immunization

Immunization FDA

GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer.

STAT+: What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s surprising rise

STAT

JANUARY 25, 2024

Gilead needs Arcellx more than ever The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business.

Recent Clinical Trials Reveal Important Updates in Adjuvant Therapy for Resectable Non–Small Cell Lung Cancer

Pharmacy Times

OCTOBER 20, 2023

Integrating immunotherapies will continue to improve patient outcomes and quality of life.

PRO-1107 by ProfoundBio Suzhou for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Non-Small Cell Lung Cancer.

JS-006 by Shanghai Junshi Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Trial of Keytruda and Lynparza Combination Fails to Meet Primary Endpoint for Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

PharmExec

MARCH 22, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

STAT+: Cancer drug shortages widen disparities between big systems and small

STAT

SEPTEMBER 25, 2023

For months, oncologist Kristen Rice found herself scrambling for cisplatin and carboplatin, two key chemotherapies used for many different cancers including ovarian, bladder, and lung cancer. Pharmacy technicians would order more drugs each day to keep the clinic running until, one day, they couldn’t.

Chemotherapy

Chemotherapy Hospitals

STAT+: Mirati wins FDA approval for KRAS-blocking lung cancer drug, but blockbuster sales hopes have dimmed

STAT

DECEMBER 12, 2022

The Food and Drug Administration on Monday approved a second KRAS-blocking treatment for advanced lung cancer. However, hopes the drug might reach a large swath of patients — and grow into a commercial blockbuster for its maker Mirati Therapeutics — have dimmed in the wake of underwhelming clinical trial results.

FDA

STAT+: The woman behind AstraZeneca’s cancer winning streak

STAT

JUNE 6, 2023

When given after surgery to the right lung cancer patients, selected using genetic tests, it cut the death rate in half. On Sunday, thousands of oncologists applauded after researchers presented data on AstraZeneca’s Tagrisso. Benjamin J. “It was a great day,” she said.

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

DF-4101 is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer.

Clinical trial begins of lung cancer immunotherapeutic

AstraZeneca’s Imfinzi tackles another type of lung cancer with latest trial win

Trending Sources

AST-001 by Ascentawits Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

Domvanalimab Combination Shows Clinically Meaningful Progression-Free Survival in Lung Cancer

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

EGFR inhibitor could provide major advance in lung cancer

Trastuzumab Deruxtecan Shows Clinical Benefit as Second-Line Therapy for Lung Cancer

Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer

AFNT-211 by Affini-T Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

Prothea debuts with $13m to develop cancer diagnostics and treatment

GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval

New Amgen immunotherapy could treat common solid tumour

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Research predicts 2029 small molecule oncology market leaders

Clinical Research Demonstrates Positive Impact of Genomic Testing for Patients with Non-small Cell Lung Cancer

Trastuzumab Deruxtecan Shows Clinically Meaningful Response in Non-Small Cell Lung Cancer

Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung Cancer

STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain

Sanofi stops development of lung cancer drug

Lung Cancer Patients Show Better Overall Survival With Atezolizumab in Clinical Trial

Chemo-free regimen demonstrates efficacy in NSCLC

Future lung cancer risk predicted from single low-dose CT scan

Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

AstraZeneca backs AI-based lung cancer diagnosis pilot in UK

Osimertinib Significantly Improves Disease-Free Survival in EGFR-Mutated Lung Cancer

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Novel vaccine delivers significant survival in lung cancer trial

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Small Cell Lung Cancer: Likelihood of Approval

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approval

NICE recommends new treatment for EGFR-positive lung cancer

STAT+: FDA finds ‘potential systemic bias’ in Amgen’s KRAS drug trial ahead of advisory meeting

Roche subcutaneous cancer immunotherapy granted MHRA approval

GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval

STAT+: What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s surprising rise

Recent Clinical Trials Reveal Important Updates in Adjuvant Therapy for Resectable Non–Small Cell Lung Cancer

PRO-1107 by ProfoundBio Suzhou for Non-Small Cell Lung Cancer: Likelihood of Approval

JS-006 by Shanghai Junshi Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval

Clinical Trial of Keytruda and Lynparza Combination Fails to Meet Primary Endpoint for Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

STAT+: Cancer drug shortages widen disparities between big systems and small

STAT+: Mirati wins FDA approval for KRAS-blocking lung cancer drug, but blockbuster sales hopes have dimmed

STAT+: The woman behind AstraZeneca’s cancer winning streak

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Stay Connected